We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Tests Show Potential for Colorectal Cancer Detection

By LabMedica International staff writers
Posted on 31 Jul 2025

Colorectal cancer remains the second leading cause of cancer-related deaths in the United States, yet many individuals miss screening due to fear, limited access, or the burdens of test preparation. More...

Early detection through regular screening is critical to reducing mortality. Traditional screening methods such as colonoscopies and stool-based tests, though effective, are often underutilized.

Blood-based screening offers a convenient, non-invasive alternative, especially for patients unwilling or unable to undergo more invasive procedures. However, for these tests to be effective in lowering cancer rates, they must be followed by diagnostic confirmation. Now, a study has revealed that colonoscopy rates after abnormal blood-based screening results mirror those for stool-based tests, but timely follow-up still remains a challenge.

The study, led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center (Los Angeles, CA, USA), evaluated Shield, a blood-based colorectal cancer screening test developed by Guardant Health (Palo Alto, CA, USA). The team conducted a retrospective analysis using medical claims data from more than 6,000 individuals aged 45 and older who underwent screening with Shield between 2022 and 2024. Their analysis focused on the 452 individuals who received abnormal results and assessed the proportion who went on to complete a colonoscopy within six months.

The study found that while blood-based tests offer a more convenient option for colorectal cancer screening, only 49% of patients completed a follow-up colonoscopy within six months, and just 56% did so at any point during the two-year study period. A further examination of demographic and insurance-related factors revealed that patients enrolled in Medicare Advantage were significantly less likely to pursue follow-up compared to those with private insurance, while individuals with fewer preexisting health conditions were more likely to complete timely follow-up.

Interestingly, unlike with stool-based screening tests, race and ethnicity did not significantly influence follow-up completion. The study’s findings, published in Gastroenterology, offer important real-world insights into the implementation of blood-based colorectal cancer screening. The results underscore the urgent need for strategies that promote timely diagnostic colonoscopies following abnormal screenings. Without this critical second step, the promise of blood-based testing to save lives remains limited. Researchers emphasize that efforts should focus on patient education, system-level interventions, and policy changes to improve compliance with follow-up protocols and fully realize the benefits of this innovative approach.

“Blood-based colorectal cancer screening is promising, but it only works if individuals complete the follow-up colonoscopy. More efforts are needed to help patients follow through to actually diagnose and treat the disease,” said Dr. Folasade May, senior author of the study.

Related Links:
UCLA Health Jonsson Comprehensive Cancer Center
Guardant Health


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.